Literature DB >> 25450521

The role of eIF3 and its individual subunits in cancer.

John W B Hershey1.   

Abstract

Specific individual subunits of eIF3 are elevated or reduced in numerous human tumors, and their ectopic overexpression in immortal cells can result in malignant transformation. The structure and assembly of eIF3 and its role in promoting mRNA and methionyl-tRNAi binding to the ribosome during the initiation phase of protein synthesis are described. Methods employed to detect altered levels of eIF3 subunits in cancers are critically evaluated in order to conclude rigorously that such subunits may cause malignant transformation. Strong evidence is presented that the individual overexpression of eIF3 subunits 3a, 3b, 3c, 3h, 3i and 3m may cause malignant transformation, whereas underexpression of subunits 3e and 3f may cause a similar outcome. Possible mechanisms to explain the malignant phenotypes are examined. The involvement of eIF3 in cancer reinforces the view that translational control plays an important role in the regulation of cell proliferation, and provides new targets for the development of therapeutic agents. This article is part of a Special Issue entitled: Translation and Cancer.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Initiation factors; Protein synthesis; Translational control; cancer; eIF3

Mesh:

Substances:

Year:  2014        PMID: 25450521     DOI: 10.1016/j.bbagrm.2014.10.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  53 in total

Review 1.  Translational Control in Cancer.

Authors:  Nathaniel Robichaud; Nahum Sonenberg; Davide Ruggero; Robert J Schneider
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-07-01       Impact factor: 10.005

2.  Estrogen receptor α promotes protein synthesis by fine-tuning the expression of the eukaryotic translation initiation factor 3 subunit f (eIF3f).

Authors:  Rafael Cuesta; Adi Y Berman; Anya Alayev; Marina K Holz
Journal:  J Biol Chem       Date:  2018-12-20       Impact factor: 5.157

3.  A Transcript-Specific eIF3 Complex Mediates Global Translational Control of Energy Metabolism.

Authors:  Meera Shah; Dan Su; Judith S Scheliga; Tomáš Pluskal; Susanna Boronat; Khatereh Motamedchaboki; Alexandre Rosa Campos; Feng Qi; Elena Hidalgo; Mitsuhiro Yanagida; Dieter A Wolf
Journal:  Cell Rep       Date:  2016-07-28       Impact factor: 9.423

Review 4.  Therapeutic Opportunities in Eukaryotic Translation.

Authors:  Jennifer Chu; Jerry Pelletier
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 5.  Dynamics of IRES-mediated translation.

Authors:  Alex G Johnson; Rosslyn Grosely; Alexey N Petrov; Joseph D Puglisi
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-03-19       Impact factor: 6.237

Review 6.  eIF3: a factor for human health and disease.

Authors:  Andreia Gomes-Duarte; Rafaela Lacerda; Juliane Menezes; Luísa Romão
Journal:  RNA Biol       Date:  2017-11-13       Impact factor: 4.652

7.  A harmine-derived beta-carboline displays anti-cancer effects in vitro by targeting protein synthesis.

Authors:  Annelise Carvalho; Jennifer Chu; Céline Meinguet; Robert Kiss; Guy Vandenbussche; Bernard Masereel; Johan Wouters; Alexander Kornienko; Jerry Pelletier; Véronique Mathieu
Journal:  Eur J Pharmacol       Date:  2017-03-18       Impact factor: 4.432

8.  eIF3 Regulation of Protein Synthesis, Tumorigenesis, and Therapeutic Response.

Authors:  Ji-Ye Yin; Zizheng Dong; Jian-Ting Zhang
Journal:  Methods Mol Biol       Date:  2017

Review 9.  Heterogeneity and specialized functions of translation machinery: from genes to organisms.

Authors:  Naomi R Genuth; Maria Barna
Journal:  Nat Rev Genet       Date:  2018-07       Impact factor: 53.242

10.  Assembly of eIF3 Mediated by Mutually Dependent Subunit Insertion.

Authors:  M Duane Smith; Luisa Arake-Tacca; Adam Nitido; Elizabeth Montabana; Annsea Park; Jamie H Cate
Journal:  Structure       Date:  2016-05-19       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.